Phase I/II study augmenting TAK-659 action in relapsed/refractory AML by addition of the proteasome inhibitor Ixazomib Big Ten Cancer Research Consortium BTCRC-HEM17-092

Study Overview

The purpose of this study is to test the safety and efficacy of combining two drugs, ixazomib and TAK-659. It will also evaluate the number of patients whose tumor responded after receiving ixazomib and TAK-659.

  • IRB Number: 1905960004
  • Research Study Identifier: TX10558
  • Principal Investigator: Howard Boswell, MD

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at or by phone at (888) 264-0005.